



BIENNIAL REVIEW

Celebrating 5 Years of Mind Medicine Australia

July 2022 - February 2024

MIND MEDICINE AUSTRALIA IS SUPPORTING THE DEVELOPMENT OF PSYCHEDELIC-ASSISTED PSYCHOTHERAPIES IN AUSTRALIA AS TREATMENTS FOR KEY CLASSES OF MENTAL ILLNESS WITHIN OUR HEALTH SYSTEM.

Level 4, 479 St Kilda Road
Melbourne VIC 3004,
Australia

CONTACT

Phone: (03) 8679 6015
Email: admin@mindmedicineaustralia.org
www.mindmedicineaustralia.org

Fast Facts.....	3
A Message From Our Chair and Executive Director.....	4
Our Board.....	10
Our Vision.....	11
What are Psychedelic-Assisted Psychotherapies?.....	12
Successful TGA Application.....	14
Certificate in Psychedelic-Assisted Therapies (CPAT).....	18
Our Events.....	21
Our Podcast.....	24
Our Book.....	25
Our People.....	26
With Thanks.....	29
Corporate Governance.....	30
Financial Reports.....	31

“I felt like I went through 15 years of psychological therapy in one night.”
— Patient featured in “Trip of Compassion”

- In February 2023, **MDMA and psilocybin were rescheduled from being prohibited substances to controlled drugs on a restricted basis, making Australia the first country in the world** to accord them this status.
- In January 2024, **the first patients in Australia received treatment with psychedelic-assisted therapy** as part of the Therapeutic Goods Administration's (TGA) Authorised Prescriber (AP) program with medicines and training supplied through Mind Medicine Australia.
- The medicines used in these therapies have shown **positive results for both safety and efficacy in clinical trials with no evidence of addiction.**
- A variety of psychedelic therapies are being trialled as treatments for **depression, PTSD, anxiety, end-of-life distress, dementia, anorexia and eating disorders, OCD, and opioid, alcohol and smoking addictions** and a number of other illnesses.
- These therapies are showing **remission rates of up to 60-80% after just 2-3 treatments** when used in combination with psychotherapy.
- There have been **over 300+ trials** in the past decade.
- Both psilocybin-assisted psychotherapy for major and treatment-resistant depression as well as MDMA-assisted psychotherapy for PTSD have been granted **“Breakthrough Therapy Designation”** by the Food and Drug Administration (FDA) in the USA to fast-track the FDA's process for registration because clinical evidence to date indicates that they may demonstrate **substantial improvement over currently available therapies.**

A MESSAGE FROM OUR CHAIR AND EXECUTIVE DIRECTOR

In our first five years, we have made remarkable progress in growing public awareness of and creating access pathways for Psychedelic-Assisted Therapies in Australia. With the success of our rescheduling applications in early 2023, we are now seeing patients being treated with psilocybin and MDMA-assisted therapies for treatment-resistant depression and PTSD respectively. This is an important and historic moment for these therapies and for mental health treatment in Australia.

The TGA decision provides access to these innovative treatments for Australians suffering from treatment-resistant mental illness and paves the way to treat other illnesses such as addictions, obsessive-compulsive disorder, anorexia, cognitive decline and end-of-life stress in the future. In January 2024, the first patients were treated with psychedelic-assisted therapies in Melbourne, Australia. These were the first psychedelic medicine dosing sessions in clinical settings in 50 years.

Our goal is to build the ecosystem for these treatments in Australia. Everyone meeting the medical criteria should be able to access psychedelic-assisted therapies in medically controlled environments. Please see our key strategic objectives below.

Four Key Strategic Areas

Awareness and Knowledge Building

- All stakeholder groups
- Always focus on trial results, scientific commentary, best practice and clinical expertise
- Many forms (e.g. webinars, summits, media, presentations etc)

Patient Access

- Regulatory access gateways, protocols, rollouts
- Cost effectiveness: medicine availability
- Accessibility
- Patient Support Funding



Professional Development Program

- Part-time professional Certificate in Psychedelic-Assisted Therapies course for health practitioners (Psilocybin, MDMA, Ketamine)
- World leading Faculty
- Professional mentoring for CPAT graduates

Research

- Obtained Government Research Funding (\$15m grant round)
- Promoted establishment of Neuromedicines Discovery Centre (developing the molecules)
- Direct research funding incl. world-first psychedelic registry at ANU
- Economic analysis

Our focus is wholly clinical.

What we have achieved in five years with your support:

Awareness and Knowledge Building

- **250+ webinars, screenings and special events** attracting **50,000+ participants**.
- Facilitating **Professor David Nutt's incredibly successful Australian tour in November 2022**, where he presented to public audiences, clinicians and decision makers. This tour included a presentation to over 130 people at the TGA in relation to the rescheduling of MDMA and psilocybin.

- Launch of **free online Global Webinar Series** where World-leading experts provide illuminating presentations and conversations about the ground-breaking opportunity psychedelic-assisted therapies offer and other related topics.
- Launch of **Mind Medicine Australia Podcast series**.
- Launch of **MMA Weekly Meditation Sessions**.
- **Video animation** explaining the mental illness epidemic in Australia and the benefits of psilocybin and MDMA-assisted psychotherapy **with 80,000+ views**.
- Created a **short documentary, Science vs Stigma**, to dispel some of the myths associated with these important medicines with over **29,000+ views**.
- **Over 155,000+** views of Shroom Boom, a light-hearted music video.
- Implemented a **Board Observership program** in conjunction with VMIAC.
- Appointed as **Member of peak body, Mental Health Australia**.
- Launch of **MMA online shop** selling a range of unique merchandise including **Australia's first book of Psychedelic Healing Stories**.
- **Initiated Australia's first Essential Research poll to gauge the sentiment of the Australian public on the issue of access to psychedelic medicines** in medically controlled environments as treatments for key classes of mental illness. **67% agreed that 'People experiencing terminal illness should have the choice to use psychedelic-assisted therapy to ease end of life distress'**.
- Developed **summary of all trials taking place in Australia**.
- **Over 705,000+ visits** to the Mind Medicine Australia website.
- **Over 63,000+ followers** on our social media channels.
- **Over 650,000+ views** on our YouTube Channel.
- **Over 11,000+ visits** to our e-book about psychedelic-assisted psychotherapies.
- **Over 47,000+ people** in our database incl. over **15,000 health professionals** and **over 1000 psychiatrists**.
- **670+ donors with 4000+ donations and 80% returning donations**.
- **200+ media appearances**.
- **33+ local Chapters** around Australia and New Zealand with **2200+ members** and growing.
- **55,000+ views to our TGA How-to guide** during the 2022 public submission period.

- Presented and produced Mind Medicine Australia's inaugural **International Summit on Psychedelic Therapies for Mental Illness in November 2021**.
- **Nearly 1,000 people registered for our two-day workshop and Global Summit** from every state of Australia and more than 15 other nations.
- **Over 90,000 views** of our Summit sizzle reel.
- **Over 80,000 visits** to the Summit website.
- **Over 5000 queries received** from the Summit website.
- **110 virtual breakout rooms**.
- **32 global leaders** in the field presented on a range of topics.
- **19 major Corporate partners**.
- **Over 160 Education partners**.
- **17 Supplier Partners**.
- **15 Media Partners**.
- **8 Scholarship winners**.
- **5 Poster winners**.
- 1 global 4-day event with massive impact.

Access to Medically Approved Therapy

- **Successful submissions made to the TGA to reschedule MDMA and psilocybin from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Medicines)**, allowing limited access to MDMA and psilocybin-assisted therapies **from July 1 2023** via the TGA's Authorised Prescriber scheme.
- Granted an **Innovation Patent over an improved method of synthesis of MDMA**.
- Successfully **procured medical grade GMP standard MDMA and psilocybin for import to Australia for use in trials and as part of the TGA's Authorised Prescriber scheme** from July 1 2023. We provide equitable access to GMP quality medicine as an **exclusive distributor in Australia for Optimi Health**.
- **In January 2024, the first patients were treated with psychedelic-assisted therapies as part of the Therapeutic Goods Administration's (TGA) Authorised Prescriber (AP) program** in Melbourne, Australia with medicines and training supplied through Mind Medicine Australia. These were the first psychedelic medicine dosing sessions in clinical settings in 50 years.
- **Established the Patient Support Fund (PSF)**. Donations into this fund will provide subsidised treatment for those who otherwise could not afford it.

- **Collaborating with Health Insurers and Governments** to broaden the funding base for these therapies.
- **Developing a gold standard National Care Program, clinical protocols and standard operating practices** for psychedelic-assisted therapies in partnership with leading clinical groups around Australia.

Professional Development Program

- Our highly anticipated **Certificate in Psychedelic-Assisted Therapies** commenced in January 2021 featuring a **world class Faculty**. **By the end of 2024, there will be over 500 qualified therapists** including psychiatrists, GPs, physicians, psychologists, psychotherapists counsellors, nurses, social workers, occupational therapists, addiction specialists, paramedics and other allied health professionals.
- Confirmed **world-leading facilitators** for our Certificate in Psychedelic-Assisted Therapies (CPAT) professional development course.
- Engaged **Dr Gita Vaid (USA)** as the course's International Course Director and **Dr Eli Kotler** as the Australian Course Director for our programs from 2023 onwards.
- Described as *"the best course of its kind in the world"* by Professor David Nutt on ABC Radio National interview (UK).
- **Over 1000+ applications** received since launch.
- **Over \$434,000 raised for CPAT grants** through philanthropy to support those in regional and rural areas and therapists suffering financial hardship. Over 85 grants have been awarded so far.
- **Over 183,000+ views** of the CPAT highlights sizzle reels.
- Launch of the **Fundamentals in Psychedelic-Assisted Therapies Course** with **over 480+ participants** so far.
- Developed a **mentoring program for graduates of PAT training**, allowing ongoing professional development with global leaders in the field.
- **Recognition by key peak/membership bodies** of our professional development and training programs.
- **Key university student placement partnerships** with University of Melbourne and a **major volunteering program** established.

Engagement with University Sector and Novel Research

- Our advocacy directly led to the **largest-ever government grant in the World for psychedelic research: \$15 million awarded in 2021** through the Australian Government's Medical Research Future Fund.

- Launch of The Monash University **Neuromedicines Discovery Centre**, follows a proposal by MMA and developed over a 2-year period.
- Supported the launch of **Psychedelic-Assisted Therapy Research Registry at ANU**, which will allow for outcome data to be collected from treatment with PAT around Australia.
- **32+ current trials** of psilocybin, MDMA, LSD and Ibogaine in Australia and New Zealand.
- Developed a **BLOG**, significant education resources and partnered with Universities to disseminate these as well as sharing these via our website.
- Discussions with key University stakeholders continue.

Noteworthy from Media Releases:

- Mind Medicine Australia, **Marks 5-Year Milestone with Global Achievements in Psychedelic Therapies.**
- **Psychiatrists give the First Psychedelic Medicine Dosing Sessions in Clinical Settings in 50 Years** this Week in Melbourne Australia.
- Breaking News: The **TGA Announces the Delegate’s Final Decision to Reschedule the Use of Psilocybin and MDMA for Medical Purposes.**
- An Open Letter to the Prime Minister in November 2022.
- **TGA Expert Review Findings Support the Therapeutic Use of Medicinal Psychedelics** in Treating Mental Health Crisis in October 2021.
- Mind Medicine Australia **Launched Australia’s First Book of Psychedelic Healing Stories** in October 2021.
- Monash University announced **establishment of the Neuromedicines Discovery Centre** to Focus on Psychedelic-Assisted Therapies for the Treatment of Key Classes of Mental Illness in November 2021.
- Mind Medicine Australia hosted Australia’s Inaugural **International Summit on Psychedelic Therapies for Mental Illness** online in November 2021.
- Mind Medicine Australia **joined a global coalition launched to secure a rescheduling of psilocybin under the 1971 UN Convention on Psychotropic Substances** in January 2022.
- **New Polling** by Mind Medicine Australia **Revealed Over 60% of Australians Support Increased Access to Psychedelic Medicines** in February 2022.
- Mind Medicine Australia Lodged **New Applications for the Restricted Medical use of MDMA and Psilocybin Assisted Therapies** for Patients with Treatment Resistant Mental Illnesses in March 2022. The full applications can be found [here](#).

The progress we are making in public education was exemplified in several headline media articles including in the Australian Financial Review, The Australian, The Age, Herald Sun, The Saturday Paper and Vogue Australia and media interviews including with Channel Nine, Channel 10, The Project, ABC and numerous other TV and radio stations and online media.

In February 2023 the TGA announced that MMA’s rescheduling applications for MDMA and psilocybin were successful. This decision allows psychiatrists to apply for Authorised Prescriber status to administer psilocybin-assisted therapy for treatment-resistant depression and MDMA-assisted therapy for PTSD. Our primary focus over the next couple of years will be on facilitating the roll out of psilocybin and MDMA-assisted psychotherapy in light of this regulatory change. We are also interested in novel research in this rapidly emerging field to treat a variety of conditions.

Behind the scenes, we are working closely with key stakeholders to ensure that these therapies will be accessible and affordable to all Australians needing these treatments in medically controlled environments, so that cost and geography doesn’t become a barrier.

In the last five years, we have assembled a comprehensive leadership team with **expertise in mental illness including psychology, neuroscience and pharmacology, non-profit development, business practices and networks, public health, events, marketing and educational development.**

Mind Medicine Australia is also supported by an outstanding **Board, Ambassadors, and an Advisory Panel of over 70 local and international experts** in medicine, psychiatry, psychology, pharmacology, research, science more broadly, ethics, law, policy, anthropology, business and therapeutic practices. We have also developed a **Lived Experience** and **Young Leaders Panel**.

As we move through 2024, our vision and capacity continue to grow. With these medicines now legally available in Australia on a restricted basis, **we turn our focus toward ensuring they are accessible and affordable to all Australians who meet the medical criteria.**


We ask for your continued and expanded support so that we can fund the path for psilocybin and MDMA-assisted psychotherapy to help treat the millions experiencing key mental illnesses in Australia. This is personal for every one of us.

As Carl Jung said, “The sole purpose of human existence is to kindle a light in the darkness of mere being.”

With gratitude for your interest and generosity. There has never been a more important time to support innovation in the treatment of mental illness.



Peter Hunt AM
Chair



Tania de Jong AM
Executive Director

OUR BOARD



Peter Hunt AM
CHAIR

Co-founder Mind Medicine Australia, Investment Banker & Engaged Philanthropist; Founder, Women's Community Shelters



Tania de Jong AM
DEPUTY CHAIR

Co-founder Mind Medicine Australia, Founder Creative Universe, Creativity Australia The Song Room, Umbrella Foundation & Creative Innovation Global



Dr Eli Kotler
DIRECTOR

Medical Director at Malvern Private Hospital, Consultant Psychiatrist, Addiction and Trauma expert



Monojit (Mono) Ray
DIRECTOR

CEO & Founder, ConnectAlex; Non-Executive Director, Kidney Health Australia



Hon Andrew Robb AO
DIRECTOR

Australia's Minister for Trade and Investment (2013-2016); Chair of Asia Link



Nicholas Smedley
DIRECTOR

Chairman, Respiro Limited

OUR VISION

Mind Medicine Australia is Australia's leading not-for-profit organisation working on the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering and suicides caused by our accelerating mental illness epidemic in Australia, through expanding the treatment options

Mind Medicine Australia is a registered charity founded by **Tania de Jong AM** and **Peter Hunt AM**. We are supporting clinical research and working towards regulatory-approved and evidence-based psychedelic-assisted therapies. We connect and educate medical practitioners, consumers, academia, government, industry, regulatory bodies, philanthropists, investors and other stakeholders.

Mind Medicine Australia is currently focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses. Our focus is wholly clinical.



MIND MEDICINE
A U S T R A L I A




INTRODUCTION TO PSYCHEDELIC ASSISTED PSYCHOTHERAPIES

Psychedelic-assisted therapies typically involves **'talk-therapy' alongside the ingestion of a psychedelic such as psilocybin or MDMA**. Researchers and clinicians often describe three distinct therapy phases:

1. Preparation
2. The acute psychedelic experience
3. Integration

The non-psychedelic elements of this approach are essential for both **effectiveness and safety**.

These 3 phases are illustrated in the timeline below.



Various approaches to preparation have been developed, from diet to psychotherapy. In clinical trials, participants will typically attend a number of talk-therapy sessions with a trained therapist who will be in attendance during the psychedelic session. A therapeutic alliance is developed during this time, and the nature of the individual's struggle is explored.


During the psychedelic session, **'set' and 'setting' are considered paramount**. 'Set' refers to mind-set, a complex mix of more transient phenomena like expectation and mood, and more enduring phenomena like personality and past experience. 'Setting' refers to the context or environment in which the session takes place, including basic factors like the comfort and aesthetic quality of the room, and more complex factors like the quality of the relationship with the clinicians and the mood they help to set. Whilst many modern clinical trials occur within hospitals or research institutes, the **session rooms are made to appear as comfortable living rooms**. There are typically **two therapists in attendance**.

The patient can sit or lie on a couch, is often encouraged to wear eyeshades, and sometimes listen to a carefully-selected playlist of music. Oral ingestion of a capsule of synthesised psychedelic compound (e.g., psilocybin) is the most common route of administration, and the session will typically last for about 8 hours.

A common therapeutic approach during psychedelic sessions is to be non-directive: attentive but usually silent, supporting the emerging process, offering assistance and guidance if needed, listening and responding to the patient when they speak, with little analysis of the material. In some trials, a single high-dose psychedelic session occurs; in others, there are two or three high-dose sessions. Many trials are also **placebo-controlled**, wherein the patient will usually have one placebo session – sometimes a very low dose of the psychedelic, sometimes an 'active placebo' that produces some noticeable somatic effects – in addition to their high-dose session(s).

Immediately after the psychedelic session and in the following days, a process of **integration** is facilitated by the therapist. During these conversations, the patient has the opportunity to process, make sense of, and give meaningful expression to their psychedelic experience.

Psychedelic-assisted therapies have shown strong clinical results. **Medicinal psilocybin and medicinal MDMA are very safe to use in a medically controlled environment and are non-addictive**. Whilst MDMA is focused on the medicinal use of psilocybin and MDMA, it should be noted that contrary to some assertions these are also amongst the safest recreational drugs.



Source: Nutt, D and Castle, D, et al. (2019) The Australian drug harms ranking study, Journal of Psychopharmacology, Vol 33, Issue 7

World First

Psilocybin and MDMA are now classified as controlled medicines in Australia.

Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

Prescribing will be limited to psychiatrists, given their specialised qualifications and expertise to diagnose and treat patients with serious mental health conditions, with therapies that are not yet well established. To prescribe, psychiatrists will need to be approved under the *Authorised Prescriber Scheme* by the TGA following approval by a human research ethics committee. The Authorised Prescriber Scheme allows prescribing permissions to be granted under strict controls that ensure the safety of patients.

The decision acknowledges the current lack of options for patients with specific treatment-resistant mental illnesses. It means that psilocybin and MDMA can be used therapeutically in a controlled medical setting. However, patients may be vulnerable during psychedelic-assisted psychotherapy, requiring controls to protect these patients.

There are currently no approved products containing psilocybin or MDMA that the TGA has evaluated for quality, safety and efficacy. However, this amendment will allow authorised psychiatrists to access and legally supply a specified 'unapproved' medicine containing these substances to patients under their care for these specific uses.

Australia ushers in a new era of psychedelic medicine

TIME Psychedelics May Be Part of U.S. Medicine Sooner Than You Think

Forbes

Australia The First Nation To Approve The Legal Use Of MDMA And Psilocybin

BBC NEWS Australia legalises psychedelics for mental health

sky news .COM.AU

TGA's approval of MDMA and Psilocybin for medical use is a result of 'renewed interest'

FINANCIAL REVIEW

Biotechs scramble as Australia leads world in psychedelics

THE AUSTRALIAN

World-first psychedelics treatment approved for PTSD and depression

Common Dreams

Australia Legalizes Therapeutic Use of MDMA and Psilocybin

Daily Telegraph

MDMA and psilocybin recently approved for medical use

perth now

MDMA: World first as Australia's Therapeutic Goods Administration recognises party drug as medical treatment for PTSD

The Canberra Times

Australia to reclassify MDMA as medicine

euronews.next

Australia just legalised MDMA to treat mental health. Could Europe do the same?

MensHealth

Australia Will Legalise Mushrooms And MDMA For Medical Use

3AW MELBOURNE

Doctor says MDMA and psilocybin treatment will have a 'significant' impact

ABC NEWS

TGA approves psilocybin and MDMA for use in treating depression and PTSD


ABC NEWS

TGA approves psilocybin and MDMA for use in treating depression and PTSD

ABC NEWS

TGA approves psilocybin and MDMA for use in treating depression and PTSD

From Our TGA Application to Successful Rescheduling



SUCCESSFUL TGA RESCHEDULING

In February 2023, the TGA approved Mind Medicine Australia's application to reschedule psilocybin and MDMA from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard. With this rescheduling, psychiatrists who are given approval from the TGA are now able to prescribe psilocybin for treatment-resistant depression and MDMA for PTSD. These changes came into effect July 1st, 2023.

The TGA's decision to reschedule these substances for medical purposes on a restrictive basis is the culmination of Mind Medicine Australia's (MMA) applications lodged in March 2022 and our objections to the interim decisions lodged in November 2022. The decision recognises the enormous number of Australians who lodged their submissions in support and the fact that treatment resistant patients aren't benefitting from currently available treatments. Australia can be very proud of the fact that we are the first nation in the World to reschedule these medicines for medical purposes and Australia is now an innovative leader in the treatment of mental illness.

You can find out more about it in the TGA's announcement and MMA's media release at: mindmedicineaustralia.org.au/tga

Psychiatrists who have undergone specialist training in psychedelic-assisted therapy can apply to become an Authorised Prescriber of psilocybin for treatment-resistant depression and MDMA for PTSD. To do so, they are required to make a submission to a Human Research Ethics Committee (HREC) that outlines details of their proposed approach including protocols, clinical rationale, training and more. Once approved by an ethics committee, they can apply with the TGA for Authorised Prescriber status, which allows them to prescribe and administer MDMA and psilocybin under the restrictions outlined above.

First Psychedelic Medicine Dosing Sessions in Clinical Settings in 50 Years in Melbourne Australia

In January 2024, the first two patients received treatment with psychedelic-assisted therapy as part of the Therapeutic Goods Administration's (TGA) Authorised Prescriber (AP) program in Melbourne, Australia with medicines supplied through Mind Medicine Australia. Both psychiatrists, Dr Eli Kotler and Dr Ted Cassidy, graduated from the first cohort of MMA's Certificate in Psychedelic-Assisted Therapies (CPAT) and further psychiatrists have since also begun treatments.

This marks the first time patients have received these treatments outside of research in a legal, regulated clinical setting with scheduled psychedelic medicines in over 50 years.

"This marks the beginning of a major shift in our mental healthcare system. The many Australians who are suffering with mental illness are deeply grateful to the TGA for its leadership."
Peter Hunt AM, Chair of Mind Medicine Australia

"This is a hopeful step toward a mental health system which heals humans rather than treats psychiatric disorders, and which values integration over managing symptoms."
Dr Eli Kotler, Psychiatrist

"The hallmark feature of the mystical experience, that we can now occasion with high probability, is the sense of the interconnectedness of all things – a sense of unity, a sense of openheartedness or love, and a noetic quality suggesting that this experience is more real than everyday waking consciousness. I believe that the experience of unity is of key importance to understanding the potential existential shifts that people can undergo after having these kinds of experiences."

Professor Roland Griffiths

CERTIFICATE IN PSYCHEDELIC ASSISTED THERAPIES (CPAT)

Our Certificate in Psychedelic-Assisted Therapies (CPAT) has successfully trained 360+ medical, mental health, and allied health clinicians to date.

The Certificate in Psychedelic-Assisted Therapies (CPAT) by Mind Medicine Australia (MMA) is a part online and part face-to-face professional training that provides registered healthcare professionals with the knowledge and skills to safely and effectively administer psychedelic-assisted therapies (PAT) in clinical settings. This program is both for prescribing psychiatrists, as well as other mental health professionals who will be delivering the treatment as part of a multidisciplinary team.

It teaches best practice for the delivery of PAT, with a focus on psilocybin, MDMA and ketamine-assisted therapy. These are the three psychedelic medicines with regulatory approval in Australia. Professor David Nutt of Imperial College London described our training as "the best training of its kind in the world". It is staffed by an **industry leading international faculty** of pioneers that are **delivering gold standard training protocols** to Australian clinicians.

Our Faculty

The training is delivered by a world-class faculty made up of global leaders in the field. Our course directors, Dr Gita Vaid (USA) and Dr Eli Kotler (AUS) are two leading psychiatrists. Our faculty also includes Dr Gabor Maté CM (Canada), Dr Bessel van der Kolk (USA), Dr Rick Doblin (USA), Prof David Nutt (UK), Dr James Fadiman (USA), and more.



Dr Gita Vaid
USA

International Course Director



Dr Eli Kotler
AUS

International Course Director



Dr Lauren MacDonald
UK

Residential Facilitator



Dr David Erritzoe
UK

Residential Facilitator



Dr Gabor Maté CM
CANADA



Dr Bessel Van der Kolk
USA



Dr Rick Doblin
USA



Prof David Nutt
UK



Hear from our Students

"A truly ground-breaking course on a new-old area of psychiatry. A must for anyone interested in challenging their preconceptions and offering something new to their patients. Delivered by a world class faculty and thoroughly recommended."

Dr Kevin Ong, Psychiatrist, VIC

"This is by far the best PD course that I have ever attended! (Having attended over thirty different workshops, and PD of all sorts). To the facilitators and teachers: there are honestly not enough sufficient words to express my gratitude and appreciation to you!"

Tamryn Morgan, Psychologist, NSW

"This training not only marries scientific, Western, research-based knowledge with ancient, age-old, holistic knowledge. It puts the participant through a journey as well. Change is not only individual. It is not only in groups. It is all of the above. And more."

Dr Paul Meens, Psychiatrist, New Zealand

Learn more about the course and apply for our next intakes at: cpat.mindmedicineaustralia.org.au

OUR EVENTS

Hear from our Students

"I'm a doctor, an Aboriginal grandmother. The CPAT course was a highlight in a lifetime of learning experiences. The impressive cadre of teachers and colleagues gave us a feeling of privileged connection. I loved our teachers. And seeing what our colleagues brought with them to the Residential made it a memorable, mind-expanding and spirit-nurturing experience. It's not often in the world that a group of people comes together knowing they can create something beyond the ordinary. This course was that. I got smarter in the many different kinds of intelligence. I feel ready to use what I've learned to care for people in a profound, powerful way." **Dr Janelle Trees, General Practitioner, VIC**

"Any self-proclaimed 'evidence based' clinician should do this course. Psychedelic medicine is here; learn about it and you will not only understand it better, but it may reinvigorate your career." **Dr John Farrow, General Practitioner, NSW**

"The CPAT course covers all didactic material relevant to 'psychedelic therapy' delivered by international and Australian experts. The 'retreat', led by experienced facilitators, is the peak and heart of the course, giving trainees a deep, natural, transpersonal, drug-free experience of mimicking the psychedelic state." **Dr Stephen Proud, Psychiatrist, WA**

"The MMA course was such an incredible collaboration of science and soul, mind and heart, knowledge, and gnosis. Not only were we given all the education and skills to do this work, but we were also given the deep exposure into psyche, to ensure that we do it with compassion, professionalism, and reverence. I'm so excited for the future of psychiatry thanks to MMA." **Ashe Young, Psychotherapist, WA**

"I have found the CPAT course very educational. I feel that my understanding of the medicine has improved, and the course has prepared me to both sit with patients on the medicine and to help them integrate their experiences. I would highly recommend this course to other practitioners interested in this emerging science." **Rimona Burke, GP, NSW**

"I had a great, meaningful time. It's so rare to bring a group of people with the same interest and passion for self-growth and helping others together. This world suffers from a huge PTSD and needs this so much. Thank you." **Helena Andrejkova, Counsellor, NSW**

"The course was exceptional. The content was so well put together and delivered by extremely professional presenters. Ben and Lauren were completely amazing. I felt challenged and held throughout the entire experience and the balance of 'head' and 'heart' worked very well. The breathwork was the highlight of my experience. I went into the session with a lot of anxiety but felt completely safe and held by both my sitters and the facilitator. Craig and Maurizio have an incredible presence and skill at creating a safe container. Overall, I would strongly recommend anyone thinking of doing the course to jump in and expand your mind and heart. Thank you all." **Susann Keating, Psychologist, WA**

"I came to acquire knowledge about being a psychedelic therapist, and I got that, and so much more! This was such a mind-expanding, heart-opening experience. If you are curious follow your instinct, enrol, and enjoy the journey!" **Angie Randell, Psychologist, QLD**

Since our launch, we have had over **200+ webinars, screenings and special events** with renowned international speakers attracting **41,000+ participants**. Our lineup of Australian and international speakers has included MAPS founder **Dr Rick Doblin (USA)**, Psychiatrist **Dr Stanislav Grof (Czech)**, Physician and Author **Dr Gabor Maté (Canada)**, Psychedelics Researcher **Dr Robin Carhart-Harris (UK)** and many more.

In addition to our own educational events, we have also taken part in many education partnership events, such as the ACNEM and Psytech conferences.

Our Global Webinar Series

Join our webinar:
Trauma, Illness & Healing in a Toxic Culture
How psychedelic-assisted therapies can help us heal from a range of mental stresses.
December 5, 1:00 PM AEDT | Live Webinar
Speaker: **Dr Gabor Maté CM (Canada)**

Free Webinar
Psychodrama and Ketamine-Assisted Psychotherapy
A Novel, Accelerated Treatment Approach
November 22, 12:00 PM AEDT | Free Live Webinar
Speakers: **Dr Bessel van der Kolk and Dr Gita Vaid**

Free Webinar
Preparation for Embodied and Integrated Healing with plant based medicine
September 21, 1:00 PM AEDT | Free Live Webinar
Speakers: **Mason Taylor and Dr Mario Alam**

Join our free webinar series!
Psychedelic therapeutics: What we know, what we think, and what we need to research
With Professor David Nutt (UK)
Wednesday 15 February 2023, 8:00pm (AEDT)

Join our free webinar series!
How Psychedelic Therapy Works
With Dr Robin Carhart-Harris (USA)
Wednesday 15 March 2023
1:00pm - 2:15pm (AEDT)

Join our free webinar series!
Issues Involved in Drug Development with MDMA-Assisted Therapy for PTSD
With Dr Rick Doblin (USA)
Wednesday 26 April 2023
1:00pm - 2:15pm (AEDT)

"Thank you so much for making it possible for us to learn all these incredible therapies and practices, and to listen to the leading scientists and doctors in the field...Cutting edge research, new innovative approaches. World famous people. I can go on and on and on! Thank you all for your work!" - **Baiba Baika, Germany**

OUR EVENTS

Professor David Nutt's (UK) Australian Tour

We were delighted to bring Professor David Nutt from Imperial College London to Australia to educate Australians about psychedelic-assisted therapies and endorse fair access to these life-saving treatments.

Professor Nutt met with representatives and stakeholders from Government, Academia, and Regulatory bodies to emphasise the safety and efficacy of psychedelic-assisted therapies to cure a range of mental illnesses. He presented at events and public lectures in Byron Bay, Canberra, Sydney and Melbourne, including high level meetings with Federal and State Governments.



Celebrating 5 Years of Mind Medicine Australia

In February 2024, we celebrated the first five years of Mind Medicine Australia with members of our team, board, advisory panel and key contributors.

In this significant period of growth and impact in a rapidly emerging field, we have been at the forefront in advocating for the potential of psychedelic-assisted therapies to treat certain classes of chronic mental health conditions and in developing the required supportive infrastructure.

Peter Hunt AM, Chair of MMA, expressed his gratitude for the collective efforts that have led to these world-leading achievements: *"As we celebrate five years of tireless dedication and progress, we are humbled by the impact we are having on the mental health landscape in Australia. The rescheduling of MDMA and Psilocybin marks a historic moment, and we remain committed to fostering accessibility and understanding of these innovative therapies and ensuring that Australia remains at the forefront of innovative treatments for the benefit of people suffering from mental illnesses."*

Tania de Jong AM, Executive Director of MMA, reflects that: *"The last five years have been a journey of discovery, advocacy, and progress. We thank everyone who has provided such strong support to help us achieve our mission. We look forward to further collaboration with the medical community, government, and the public to ensure that psychedelic-assisted therapies become an integral and accessible part of mental healthcare in Australia. It is an honour and privilege to have founded a charity that can help humanity to heal."*



OUR PODCAST



In 2023, we launched the second season of the Mind Medicine Australia Podcast, where we explore breakthrough innovations for mental illness.

The Mind Medicine Australia Podcast aims to connect, listen and share the power of lived experience stories of psychedelic-assisted therapy and mental health to inform research directions, policy and system change.

In the podcast, you'll hear about the real experiences of people who have endured and recovered from mental ill-health using psychedelic-assisted therapy. As a part of this exploration, we explore related tools and experiences that our guests have used to cultivate and maintain wellbeing.


Hosted by Deb Roberts

Dr Deb Roberts, PhD is the podcast host for the Mind Medicine Australia Podcast 'Season 2' and has been a MMA volunteer, guides the weekly staff meditation, on the MMA Lived Experience Panel and has a life-long relationship with mental (ill) health yet been able to navigate a fulfilling existence through various means.

She is deeply passionate about conversations related to wellbeing. She uses her own lived experience as well as the reality of having two family members who ended their life seeing no treatment pathway forward. One was her older sister who tried countless medicine combinations, therapies and facilities over 30 years.

Listen to the podcast on Spotify or Apple Podcasts: mindmedicineaustralia.org/podcast

OUR BOOK



Mind Medicine Australia has released a book sharing the psychedelic healing stories of 53 Australians, in their own words. Launched during Mental Health Month in October 2021, this first Australian book of true stories further reinforces the life-changing and life-saving impact of psychedelic-assisted therapies for a range of mental illnesses and addictions.

This book was created to **raise awareness among the general public about the healing potential of psychedelics and to reduce stigma** around their use. It also provides a platform for selected authors to share their experiences of hope and healing, and have their voices heard to advocate for the therapeutic use of psychedelics.

With the help of our extensive Chapter network throughout Australia, **we compiled the stories of 53 Australians**, asking them:

1. What led you to seek healing through psychedelic medicine?
2. What was your psychedelic experience like?
3. How have you been able to integrate this experience?
4. How has it contributed to your healing process?

This book will show you the deeply human side of the effect this medicine can have, and give you hope, inspiration and clarity around what is possible for Australians when we get fair access to these breakthrough medicines. **Available in hard copy or e-book at:** shop.mindmedicineaustralia.org

OUR PEOPLE

AMBASSADORS

Dr Rick Doblin (USA)

Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS)

Professor David Nutt (UK)

Head of Neuropsychopharmacology at Imperial College London

The late Professor Roland Griffiths (USA)

Professor of Psychiatry and Behavioural Sciences at Johns Hopkins School of Medicine

Dr Bill Richards (USA)

Psychologist in the Center for Psychedelic and Consciousness Research at the Johns Hopkins School of Medicine

BOARD OF DIRECTORS

Peter Hunt AM (Chair)

Co-founder Mind Medicine Australia, Investment Banker & Engaged Philanthropist; Founder, Women's Community Shelters

Tania de Jong AM (Deputy Chair)

Co-founder Mind Medicine Australia, Founder, Creative Universe, Creativity Australia, The Song Room & Creative Innovation Global

Dr Eli Kotler

Medical Director at Malvern Private Hospital. Consultant Psychiatrist, Addiction and Trauma expert

Mono Ray

CEO & Founder, ConnectAlex; Non-Executive Director, Kidney Health Australia

The Hon Andrew Robb AO

Australia's Minister for Trade and Investment (2013-2016); Chair of Asia Link

Nicholas Smedley

Chairman, Respire Limited

ADVISORY PANEL

Dr Scott T. Aaronson (USA)

Director of Clinical Research Programs, Sheppard Pratt Health System and Adjunct Professor in the Department of Psychiatry, University of Maryland

Dr Tanveer Ahmed

Psychiatrist and Author

Dr Mario Alam

Holistic General Practitioner, Founder of the Reset Retreats Centre and the RESET program

Prof Chris Bache

Professor Emeritus in the department of Philosophy and Religious Studies at Youngstown State University

Greg Barns

Barrister, Author & Company Director

Prof Ian E. Brichtope

Director of Nutrition and Environmental Medicine, NIIM

Elizabeth Bryan AM

Company Director

Francoise Bourzat (USA)

Psychedelic Guide Trainer and Author

John Burgos (USA)

Teacher and Speaker

Cathy Burke

Speaker, Author, Global Change Maker

Prof Jane Burns

Chair of Open Arms, Chair of STREAT and Chair of the Centre for Mental Health, Swinburne University

Dr David Caldicott

Emergency Medicine Consultant

Prof Robin Carhart-Harris (UK)

Ralph Metzner Distinguished Professor, Weill Institute for Neurosciences and University of California San Francisco

Dr Ted Cassidy

Psychiatrist and Co-Founder of Monarch Mental Health Group

Rita Chowdhury

Lawyer

Prof Arthur Christopoulos

Dean, Faculty of Pharmacy & Pharmaceutical Sciences, Monash University

Bruce Clarke

Chairman, Allygroup Pty Ltd

Dr Wade Davis CM (Canada)

Anthropologist and writer

Carroll Dunham

Medical Anthropologist

Wesley Enoch AM

Writer and Director

Dr David Erritzoe

Psychiatrist and Neuroscientist

Dr James Fadiman (USA)

Psychologist and Author

Robert Falconer (USA)

IFS Practitioner

Amanda Feilding (UK)

Founder and Executive Director of the Beckley Foundation

Prof Paul Fitzgerald

Director at ANU School of Medicine and Psychology and Director of the Epworth Centre for Innovation in Mental Health

Prof Ian Freckelton QC

Queen's Counsel and Supreme Court Judge of Nauru

Prof Paul Frijters (UK)

Research Fellow London School of Economics

Prof Dr Karl J. Friston (UK)

Scientific Director: Wellcome Centre for Human Neuroimaging and Professor: Queen Square Institute of Neurology

Dr Albert Garcia-Romeu (USA)

A/Professor Johns Hopkins University School of Medicine

Dr David Gaskell

Medical Director and Rural Generalist

Dr Suzy Green

Clinical and Coaching Psychologist (MAPS) and Founder and CEO of The Positivity Institute

Dr George Halasz

Consultant Child and Adolescent Psychiatrist and Adjunct Senior Lecturer, Monash University

Dr Rachel Harris (USA)

Psychologist and Author

David Heilpern

Dean of Law at Southern Cross University

Prof Gregg Henriques (USA)

Clinical Psychologist at James Madison University

Tommy Huppert

Founder and CEO of Cannatrek Limited

Prof Matthew W. Johnson (USA)

Susan Hill Ward Professor of Psychedelics at Johns Hopkins University School of Medicine

Mark Joiner

Business Strategist, Non-Executive Director and Finance Executive

Rabbi Jeffrey Kamins OAM

Rabbinic Advisor and Founder at Voiceless

Helen Kapalos

Journalist, Filmmaker and Advocate

Anouk Koopman-Daemen

Clinical Research Specialist

Dr Jennifer Loughman

General Practitioner

Pastor Graham Long AM

Former Pastor at The Wayside Chapel, Sydney

Dr Paul MacLeman

Corporate Advisor

Dr Sam Manger

General Practitioner, Senior Lecturer and Academic Lead in Lifestyle Medicine, James Cook University College of Medicine

Dr Gabor Maté CM (Canada)

Physician and Author

Dr David E. Nichols (USA)

Psychedelic Chemist and Adjunct Professor, University of North Carolina

Prof Dr Kylie O'Brien

Adjunct Professor, Torrens University, South Australia

Dr Thomas Pogge (USA)

Philosopher and Professor of Philosophy and International Affairs, Yale

Nigel Pollard

Medicine Business Specialist and Chair at Natural Health Science Foundation

Dr Stephen Proud

Psychiatrist

Sara Reed (USA)

Licensed Marriage and Family Therapist and psychedelic research therapist at Imperial College London

Dr Reid Robison (USA)

Psychiatrist, Researcher & Chief Medical Officer, Novamind

Prof Jeffrey Rosenfeld AC, OBE

Senior Neurosurgeon at the Alfred Hospital; Emeritus Professor Monash University

Dr Arne Rubinstein

Founder & CEO, The Rites of Passage Institute

Dr James Rucker (UK)

Consultant Psychiatrist & Senior Clinical Lecturer, King's College London

Dr Mark Ryan

Psychiatrist

Dr Stuart Saker

General Adult Psychiatrist with an interest in Veterans' Mental Health

Prof Avni Sali AM

Physician, Founding Director of National Institute of Integrative Medicine and Member of the Scientific Board of The European Congress for Integrative Medicine

Dr Oscar Serrallach

Medical Doctor

WITH THANKS

Janine Shepherd AM

Speaker and Author, Disability Advocate

Dr Ronald D. Siegel (USA)

Assistant Professor of Psychology, Harvard Medical School

Licia Sky

Co-founder of the Trauma Research Foundation

Dr Patrycja Slawuta (USA)

Behavioural Scientist and Founder at SelfHackathon

Dr James Stewart

GP, Cannabinoid Clinician, Doctor of the Year and Peoples Choice Award at the National Cannabis Industry Awards

Prof Margaret Somerville

Bioethicist at University of Notre Dame Australia

Dr Jack Springer (USA)

Emergency Physician

Attila Szabo (Norway)

Research Fellow – University of Oslo

Imam Tawhidi

Islamic Scholar, Educator, Author, Global Speaker and Vice President of The Global Imams Council

Prof John Tiller

Professor Emeritus of Psychiatry, University of Melbourne

Dr Janelle Trees

Rural and Remote Doctor, Educator

Dr Gita Vaid (USA)

Psychiatrist, Psychoanalyst and Co-Founder at Center for Natural Intelligence

Dr Bessel van der Kolk (USA)

Professor of Psychiatry, Boston University School of Medicine and President, Trauma Research Foundation

Dr Alberto Villoldo (USA)

Founder the Four Winds Society, Director the Center for Energy Medicine (Chile)

Dr Ross Walker

Consultant Cardiologist, Media Commentator and Advisor

Dr Jeremy Weate

Chief Executive Officer, Eastr Health

Dr Michael Winkelman (USA)

Leader in neurotheological perspectives on shamanism, traditional healing practices, and altered states of consciousness

Dr Alex Wodak AM

Physician, Director of Australia 21 and President of the Australian Drug Law Reform Foundation

Rabbi Dr Laibl Wolf

Dean and Founder of the Spiritgrow Wellness Centre, Melbourne Australia

EXECUTIVE TEAM

Tania de Jong AM

Executive Director

Scott Edwards

Executive Officer

Ilan Hayman

Head of Operations

Nicole Hearnden

Events and Partnerships Manager

Markus Body

Administration Officer

Julia Neubauer

Digital Communications, Design and Social Media Consultant

Brenda Turner

Accounts

Carey Handfield

Bookkeeper

Spud

Chief Puppy Officer (CPO)

MAJOR INDIVIDUAL SUPPORTERS

Belinda Bardas

Paul Cave

Lewis Gale

Stephen Grant and Sue Petruszka

Steve Grimley

Mark Joiner

Antony de Jong

Andrew Larsen

Michael Norster

Harry Rosenberg

Nicholas Smedley

Janine Taranto

Broderick Westrope

Ray Wilson and Plenary Group

TRUST AND FOUNDATION SUPPORTERS

Entrepreneurs Organisation

G G Aviation Pty Limited (Tony Shields)

Hunt Family Foundation

Laser Image Pty Ltd

Sofia Foundation Pty Ltd ATF

The L & R Uechtritz Foundation

Veith Foundation

IN-KIND SUPPORTERS

Australian National University

Aus Vitality

Byron Community Centre

Creative Universe

Creativity Australia and the With One Voice Choirs

City of Port Phillip

Dr Deb Roberts

Drug Science UK

Earth Heroes

Elektra Magnesium

Heaps Normal

Highbration

Mandala Wines

Murchisons

Pana Organic

SuperFeast

Sydney University

Tea Therapy

Uplift Community

Meetings of Directors

During the period covered by this Review, there were 4 Board Meetings of Directors. Attendances by each Director during the period were as follows:

Board member	Number eligible to attend	Number attended
Peter Hunt AM	4	4
Tania de Jong AM	4	4
Admiral Chris Barrie AC	1	1
Professor Jane Burns	4	1
Dr Eli Kotler	4	3
Dr Simon Longstaff	4	4
Monojit (Mono) Ray	4	4
Hon Andrew Robb AO	4	3
Nicholas Smedley	4	2

Company particulars

Mind Medicine Australia Limited
 ABN: 62 630 150 873
 Level 4, 479 St Kilda Road
 Melbourne VIC 3004, Australia

Mind Medicine Australia Limited is a company limited by guarantee, incorporated in Australia and having its principal place of business at the address listed above.

The charity has deductible gift recipient (DGR) status; all donations are tax-deductible.

Mind Medicine Australia
 ABN 62 630 150 873
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
 FOR THE YEAR ENDED 30 JUNE 2023

	Note	2023 \$	2022 \$
Conference income		455	573,659
Consulting patients income		-	32,192
Distributions and dividends received		225,050	-
Educational income		-	363,349
Donations - corporate		55,512	155,213
Donations - events		102,345	31,178
Donations - individuals		94,601	166,893
Donations - trusts and foundations		962,228	78,000
Grants		100,000	102,500
Other income		54,868	154,367
Gross Profit		1,595,059	1,657,351
Interest income		4,524	171
		1,599,583	1,657,522
Consulting and professional fees	3	(163,156)	(495,649)
Educational expenses		(105,961)	(61,768)
Employee benefits	3	(458,919)	(338,213)
Finance costs	3	(1,440)	(18,234)
Grant expenses		(133,000)	-
Other expenses	3	(546,555)	(364,873)
Rent		(80,899)	(64,295)
Research		(384,163)	(291)
Total Expenses		(1,874,093)	(1,343,323)
Profit / (loss) before income tax		(274,510)	314,199
Income tax expense		-	-
Net Profit / (loss)		(274,510)	314,199
Other comprehensive income:		-	-
Total comprehensive income for the year		(274,510)	314,199

Mind Medicine Australia
ABN 62 630 150 873

STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2023

	Note	2023 \$	2022 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	4	915,477	848,119
Accounts Receivable	5	69,091	25,160
Other Assets	6	232,094	215,289
Inventory	7	126,404	40,424
TOTAL CURRENT ASSETS		1,343,066	1,128,992
NON-CURRENT ASSETS			
Property, Plant and Equipment	8	11,953	3,258
TOTAL NON-CURRENT ASSETS		11,953	3,258
TOTAL ASSETS		1,355,019	1,132,250
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	9	119,084	69,908
Employee provisions	10	15,612	13,617
Other liabilities	11	791,340	345,232
TOTAL CURRENT LIABILITIES		926,036	428,757
TOTAL LIABILITIES		926,036	428,757
NET ASSETS		428,983	703,493
EQUITY			
Retained earnings		428,983	703,493
TOTAL EQUITY		428,983	703,493

Mind Medicine Australia
ABN 62 630 150 873

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2023

	Note	Retained Earnings \$	Total \$
Balance at 1 July 2021		389,294	389,294
Comprehensive income			
Profit for the year		314,199	314,199
Other comprehensive income for the year		-	-
Total comprehensive income		314,199	314,199
Balance at 30 June 2022		703,493	703,493
Comprehensive income			
Profit / (loss) for the year		(274,510)	(274,510)
Other comprehensive income for the year		-	-
Total comprehensive income		(274,510)	(274,510)
Balance at 30 June 2023		428,983	428,983

Mind Medicine Australia
 ABN 62 630 150 873
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2023

	Note	2023 \$	2022 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		387,326	778,265
Payments to suppliers and employees		(1,525,102)	(1,203,742)
Interest received		4,524	171
Donations received		1,214,686	431,284
Net cash provided by operating activities	14	81,434	5,978
CASH FLOWS FROM INVESTING ACTIVITIES			
Net Payment for Property, Plant and Equipment		(14,076)	-
Net cash provided by / (used in) financing activities		(14,076)	-
Net (decrease)/increase in cash and cash equivalents held		67,358	5,978
Cash at beginning of the financial year		848,119	842,141
Cash at end of the financial year	4	915,477	848,119



*“Through our eyes, the universe is perceiving itself.
 Through our ears, the universe is listening to its harmonies.
 We are the witnesses through which the universe becomes
 conscious of its glory, of its magnificence.”*

Alan Watts

Mind Medicine Australia
 Level 4, 479 St Kilda Road
 Melbourne VIC 3004, Australia
 Phone: (03) 8679 6015
admin@mindmedicineaustralia.org
www.mindmedicineaustralia.org